Stockreport

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics, Inc.  (HARP) 
Last harpoon therapeutics, inc. earnings: 3/12 04:05 pm Check Earnings Report
PDF Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objecti [Read more]